Also Known As
Tesamorelin Acetate · Egrifta · TH9507
Overview
Tesamorelin is a stabilized GHRH analog approved by FDA in 2010 for HIV-associated lipodystrophy. Reduces visceral adipose tissue while increasing IGF-1.
Mechanism of Action
Stimulates pituitary GH release through GHRH receptor activation. Trans-3-hexenoic acid modification increases stability and potency.
Quick Reference
Notes
FDA-approved medication. Contraindicated with active malignancy.
Dosing Protocol
Pharmacokinetics
Administration
Reconstitution
Special Instructions
FDA-approved for HIV lipodystrophy. Inject into abdomen only. Do not inject into scar tissue.
Warnings
Contraindications
Drug Interactions
Possible Side Effects
Legal & Regulatory
Pregnancy
Molecular Data
No sources available yet.
Related Peptides
No community data available yet. Be the first to add this peptide to your inventory!